All generics articles – Page 2
-
BusinessMylan expands in dermatology
$1bn deal with Renaissance Acquisition Holdings brings 25 products and builds on Meda merger portfolio
-
BusinessIndian whistleblower pushes for regulatory reform
Although denied a hearing by India’s supreme court, Dinesh Thakur wants to shake up pharmaceutical safety laws
-
OpinionForged in righteous flames
Could the debate over pharma price-gouging have positive results for both patients and companies?
-
Business
Lilly loses UK patent challenge
Allergan’s cancer drug generics do not infringe patents, say UK courts
-
Business
GSK fined for stalling antidepressant generics
UK Competition and Markets Authority deems pay-for-delay deal illegal and imposes £45m in fines
-
BusinessMylan to buy Meda in further generics consolidation
£6.9bn deal will give combined company ‘critical mass’ in US market
-
OpinionWhat the market will bear?
Martin Shkreli’s monopolising model poses some uncomfortable questions for the pharma industry, says Derek Lowe
-
Business
Allergan steps away from generics with sale to Teva
$40.5 billion deal gives Allergan cash to clear debt and fund further acquisitions, and catapults Teva into global pharma top 10
-
Business
Teva fined $1.2bn in pay-for-delay case
Company illegally blocked generic competition of sleep disorder drug, and settlement terms tighten up rules on anticompetitive behaviour
-
BusinessGenerics firms in three-way takeover battle
Mylan is chasing Perrigo, while fending off advances from Teva
-
Business
Generics giant Mylan offers $30 billion for Perrigo
Mylan makes ambitious takeover offer just weeks after Abbott aquisition closes
-
Business
Teva buys Auspex Pharmaceuticals for $3.2bn
Generics giant will add late stage Huntingdon’s drug to CNS portfolio
-
-
Business
Teva wins generic esomeprazole race
US approval of heartburn drug after Ranbaxy version was withdrawn by regulators
-
Business
EU regulator calls for generic drug suspensions
The EMA wants hundreds of formulations off the market after identifying systematic fraud in a major Indian contract clinical research organisation
-
Business
UCB sells speciality generics subsidiary
Firm will use $1.5bn proceeds to reduce debt and concentrate on developing new drugs in neurology and immunology
-
Business
Ranbaxy sues over withdrawn US approvals
Company says decision is ‘unconstitutional’ and deprives it of hundreds of millions of dollars in revenue
-
Business
Cipla targets asthma market with Advair copy
Indian pharma company Cipla has launched a generic version of GSK’s best selling drug
-
Business
Piramal exits drug discovery in India
Company will concentrate on generic medicines and clinical and contract research.
-
Business
China struggles to speed up drug reviews
Regulator considers outsourcing reviews, and creates a fast-track scheme for priority generics
- Previous Page
- Page1
- Page2
- Page3
- Page4
- Next Page